BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Oruka Therapeutics (NASDAQ: ORKA) and has maintained a price target of $151 for the stock. This endorsement suggests confidence in the company's future performance.